Nitrates and Bone Turnover (NABT) - Trial to Select the Best Nitrate Preparation: Study Protocol for a Randomized Controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2013 Sep 10

PMID 24010992

Citations 1

Authors

Roxana C Bucur

Lauren S Reid

Celeste J Hamilton

Steven R Cummings

Sophie A Jamal

Affiliations

Soon will be listed here.

Abstract

Background: Organic nitrates uncouple bone turnover, improve bone mineral density, and improve trabecular and cortical components of bone. These changes in turnover, strength and geometry may translate into an important reduction in fractures. However, before proceeding with a large fracture trial, there is a need to identify the nitrate formulation that has both the greatest efficacy (with regards to bone turnover markers) and gives the fewest headaches. Ascertaining which nitrate formulation this may be is the purpose of the current study.

Methods And Design: This will be an open-label randomized, controlled trial conducted at Women's College Hospital comparing five formulations of nitrates for their effects on bone turnover markers and headache. We will recruit postmenopausal women age 50 years or older with no contraindications to nitroglycerin. Our trial will consist of a run-in phase and a treatment phase. We will enroll 420 women in the run-in phase, each to receive all of the 5 potential treatments in random order for 2 days, each with a 2-day washout period between treatments. Those who tolerate all formulations will enter the 12-week treatment phase and be randomly assigned to one of five groups: 0.3 mg sublingual nitroglycerin tablet, 0.6 mg of the sublingual tablet, a 20 mg tablet of isosorbide mononitrate, a 160 mg nitroglycerin transdermal patch (used for 8 h), and 15 mg of nitroglycerin ointment as used in a previous trial by our group. We will continue enrolment until we have randomized 210 women or 35 women per group. Concentrations of bone formation (bone-specific alkaline phosphatase and procollagen type I N-terminal propeptide) and bone resorption (C-telopeptides of collagen crosslinks and N-terminal crosslinks of collagen) agents will be measured in samples taken at study entry (the start of the run in phase) and 12 weeks. Subjects will record the frequency and severity of headaches daily during the run-in phase and then monthly after that. We will use the 'multiple comparisons with the best' approach for data analyses, as this strategy allows practical considerations of ease of use and tolerability to guide selection of the preparation for future studies.

Discussion: Data from this protocol will be used to develop a randomized, controlled trial of nitrates to prevent osteoporotic fractures.

Trial Registration: ClinicalTrials.gov Identifier: NCT01387672. Controlled-Trials.com: ISRCTN08860742.

Citing Articles

Nitrate Medications, Fractures, and Change in Bone Mineral Density in Postmenopausal Women: Results from the Women's Health Initiative.

Golchin N, Hohensee C, Lacroix A, Gray S J Bone Miner Res. 2016; 31(9):1760-6.

PMID: 26990305 PMC: 6171356. DOI: 10.1002/jbmr.2838.

References

Evans D, Ralston S . Nitric oxide and bone. J Bone Miner Res. 1996; 11(3):300-5. DOI: 10.1002/jbmr.5650110303. View

Ralston S, Ho L, Helfrich M, Grabowski P, Johnston P, Benjamin N . Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res. 1995; 10(7):1040-9. DOI: 10.1002/jbmr.5650100708. View

Gullberg B, Johnell O, Kanis J . World-wide projections for hip fracture. Osteoporos Int. 1997; 7(5):407-13. DOI: 10.1007/pl00004148. View

Wallin J, Sjovall J . Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther. 1981; 3(6):450-2. View

Kasten T, Patel N, Osdoby P, Krukowski M, Misko T, Settle S . Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A. 1994; 91(9):3569-73. PMC: 43621. DOI: 10.1073/pnas.91.9.3569. View

Kawai M, Modder U, Khosla S, Rosen C . Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov. 2011; 10(2):141-56. PMC: 3135105. DOI: 10.1038/nrd3299. View

Chae H, Park R, Chung H, Kang J, Kim M, Choi D . Nitric oxide is a regulator of bone remodelling. J Pharm Pharmacol. 1997; 49(9):897-902. DOI: 10.1111/j.2042-7158.1997.tb06132.x. View

MacIntyre I, Zaidi M, Alam A, Datta H, Moonga B, Lidbury P . Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A. 1991; 88(7):2936-40. PMC: 51355. DOI: 10.1073/pnas.88.7.2936. View

Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1999; 280(24):2077-82. DOI: 10.1001/jama.280.24.2077. View

10.

Nickols G, Osdoby P . Bone cell function, regulation, and communication: a role for nitric oxide. J Cell Biochem. 1995; 57(3):399-408. DOI: 10.1002/jcb.240570305. View

11.

Wimalawansa S . Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res. 2000; 15(11):2240-4. DOI: 10.1359/jbmr.2000.15.11.2240. View

12.

Lowik C, Nibbering P, Van de Ruit M, Papapoulos S . Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest. 1994; 93(4):1465-72. PMC: 294160. DOI: 10.1172/JCI117124. View

13.

Cummings S, Palermo L, Browner W, Marcus R, Wallace R, Pearson J . Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000; 283(10):1318-21. DOI: 10.1001/jama.283.10.1318. View

14.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

15.

Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7):637-45. DOI: 10.1001/jama.282.7.637. View

16.

Feelisch M . Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Heart J. 1993; 14 Suppl I:123-32. View

17.

Aguirre J, Buttery L, OShaughnessy M, Afzal F, Fernandez de Marticorena I, Hukkanen M . Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol. 2001; 158(1):247-57. PMC: 1850250. DOI: 10.1016/S0002-9440(10)63963-6. View

18.

Reginster J . Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs. 2010; 71(1):65-78. DOI: 10.2165/11587570-000000000-00000. View

19.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

20.

Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18(6):1051-6. DOI: 10.1359/jbmr.2003.18.6.1051. View